Companies
Owlstone Medical
UK-based Owlstone Medical's Breath Biopsy platform acts as the global gold standard for clinical research.
- Country
- United Kingdom
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $169.01M total raised; latest round $27M Series E (Jan 2025) | owlstonemedical.com |
| Production site | Commercial-scale Breath Biopsy Laboratory in Cambridge, UK | cambridgenetwork.co.uk · drugdiscoverynews.com · owlstonemedical.com |
| Certification | ISO 13485 certified facility | 3formdesign.com |
| Regulatory approval | OMED Health Breath Analyzer registered as a Class 1 medical device with the FDA | api.ai-analytics.org · owlstonemedical.com |
| Headcount | Over 150 employees (as of Dec 2024); 123 employees (as of Oct 2026 reporting) | owlstonemedical.com |
Independent sources: 3formdesign.com · api.ai-analytics.org · cambridgenetwork.co.uk · drugdiscoverynews.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Breathomics | diagnostics-medtech | Medium | → |
| Synthetic biomarkers | diagnostics-medtech | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.